Jazz Pharmaceuticals PLC $JAZZ Shares Purchased by California State Teachers Retirement System

California State Teachers Retirement System boosted its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 22.0% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 63,657 shares of the specialty pharmaceutical company’s stock after acquiring an additional 11,486 shares during the period. California State Teachers Retirement System’s holdings in Jazz Pharmaceuticals were worth $12,034,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of JAZZ. Royal Bank of Canada boosted its holdings in shares of Jazz Pharmaceuticals by 96.5% during the first quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company’s stock worth $8,394,000 after purchasing an additional 33,210 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in Jazz Pharmaceuticals by 147.7% in the first quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock valued at $43,652,000 after purchasing an additional 209,667 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Jazz Pharmaceuticals by 4.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company’s stock worth $24,479,000 after buying an additional 7,954 shares during the period. Focus Partners Wealth lifted its position in Jazz Pharmaceuticals by 3.4% during the first quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company’s stock worth $574,000 after buying an additional 154 shares during the period. Finally, Geneos Wealth Management Inc. boosted its stake in Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 137 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $240.47, for a total transaction of $1,442,820.00. Following the sale, the director owned 366,682 shares of the company’s stock, valued at $88,176,020.54. The trade was a 1.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Heather Ann Mcsharry sold 2,000 shares of the business’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $241.00, for a total transaction of $482,000.00. Following the completion of the transaction, the director owned 18,449 shares in the company, valued at $4,446,209. This represents a 9.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 13,098 shares of company stock valued at $3,131,906. 4.10% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms have commented on JAZZ. Weiss Ratings upgraded Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, June 29th. Leerink Partners increased their price objective on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an “outperform” rating in a report on Wednesday, April 22nd. Wells Fargo & Company raised their target price on shares of Jazz Pharmaceuticals from $265.00 to $285.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 14th. Needham & Company LLC boosted their target price on shares of Jazz Pharmaceuticals from $255.00 to $282.00 and gave the company a “buy” rating in a report on Monday, July 20th. Finally, Raymond James Financial restated an “outperform” rating and issued a $239.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $259.06.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ opened at $251.58 on Tuesday. The business’s 50-day simple moving average is $239.50 and its 200 day simple moving average is $207.30. The company has a market cap of $15.80 billion, a P/E ratio of -12,572.71, a PEG ratio of 0.22 and a beta of 0.32. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04. Jazz Pharmaceuticals PLC has a one year low of $105.00 and a one year high of $261.30.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing analysts’ consensus estimates of $6.18 by ($0.47). Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The company had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.11 billion. During the same quarter in the prior year, the company earned ($8.25) EPS. The firm’s revenue was up 15.5% compared to the same quarter last year. On average, sell-side analysts forecast that Jazz Pharmaceuticals PLC will post 21.9 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.